{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:33:48Z","timestamp":1792424028360,"version":"4.5.0"},"reference-count":20,"publisher":"Massachusetts Medical Society","issue":"23","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100009857","name":"Supported by Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2024,12,12]]},"DOI":"10.1056\/nejmoa2412309","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T15:16:42Z","timestamp":1731770202000},"page":"2231-2241","source":"Crossref","is-referenced-by-count":139,"title":["CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy"],"prefix":"10.1056","volume":"391","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-9831","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"first","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kachadourian","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Walsh","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Rocha","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4578-1977","authenticated-orcid":false,"given":"David","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Smith","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"T\u00e4ubel","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Gane","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Pilebro","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adams","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuf","family":"Razvi","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Olbertz","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Haagensen","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Xu","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adia","family":"Leung","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Sonderfan","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gutstein","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[{"name":"From the National Amyloidosis Centre, University College London, Royal Free Hospital (M.F., Y.R., J.D.G.), and Richmond Pharmacology (J.T.) \u2014 both in London; Brigham and Women\u2019s Hospital, Boston (S.D.S.), and Intellia Therapeutics, Cambridge (J.K., L.W., R.R., D.L., D.S., J.O., A.H., P.Z., Y.X., A.L., A.S.) \u2014 both in Massachusetts; the University of Auckland, Auckland, New Zealand (E.J.G.); Umea University, Umea, Sweden (B.P.); Centre Hospitalo\u2013Universitaire de Bic\u00eatre, Assistance Publique\u2013H\u00f4pitaux de Paris, University Paris\u2013Saclay, Le Kremlin\u2013Bic\u00eatre, France (D.A.); and Regeneron Pharmaceuticals, Tarrytown, NY (D.E.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305434"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409134"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107454"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.2555"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.0022"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.04.011"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.12.036"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.09.542"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.18688"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070265"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05252-1"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04433.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac363"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300757"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2023.09.028"},{"key":"e_1_3_4_21_2","unstructured":"National Institutes of Health. MAGNITUDE: a phase 3 study of NTLA-2001 in participants with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). 2024 (https:\/\/clinicaltrials.gov\/study\/NCT06128629)."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2412309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:36:00Z","timestamp":1749681360000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2412309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":20,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,12]]}},"alternative-id":["10.1056\/NEJMoa2412309"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2412309","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]}}}